Clinical Trials Browser

Phase 1 × ribociclib × Breast × Clear all

NCT05683418 2026-04-22

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Phase 1 Recruiting

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT03616587 2026-01-28

SERENA-1

Phase 1 Active not recruiting

Breast Neoplasms

NCT05996107 2026-01-28

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT05508906 2025-10-22

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT05216432 2025-09-22

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT06239467 2025-09-09

PIKture-01

Phase 1 Recruiting

Breast Neoplasms

NCT02608216 2025-09-03

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT05870579 2025-08-21

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1 Terminated

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT05759949 2025-05-16

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Phase 1 Completed

Breast Neoplasms

NCT04315233 2025-04-22

CHARGE

Phase 1 Recruiting

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT02599363 2023-11-09

A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer

Phase 1 Completed

Advanced Breast Cancer

NCT02333370 2023-06-08

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Phase 1 Completed

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Phase 1 Terminated

Advanced or Metastatic ER+ Breast Cancer

NCT02586675 2022-01-21

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Phase 1 Completed

7 enrolled 8 charts

Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT04585724 2021-10-18

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Phase 1 Withdrawn

Brain Neoplasms, Breast Neoplasms

NCT01857193 2021-04-13

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT02154776 2020-12-19

LeeBLet

Phase 1 Completed

Breast Neoplasms

NCT02088684 2020-12-17

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Phase 1 Completed

Breast Neoplasms